Price data is not available
Revelation Biosciences Inc
REVBNASDAQ
Revelation Biosciences rose 11.0% from $3.93 to $4.36, behind the S&P 500's +11.2%. Its worst day was Oct 16 (−36.3%), and its low came Oct 16 at $0.48.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Revelation Biosciences closed at its highest level of the year, 17.1% above where the year started.
+5.5% · S&P 500 +0.2%
EPS of $-1.65 beat the $-2.76 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−0.8% · S&P 500 −0.5%
EPS of $-2.71 missed the $-1.15 estimate on $0.00 revenue.
−5.9% · S&P 500 +0.8%
EPS of $-0.87 missed the $-0.83 estimate on $0.00 revenue.
+2.7% · S&P 500 +0.6%
Revelation Biosciences closed at its lowest level of the year, 87.7% below where the year started.
−36.3%, the year's worst day · S&P 500 −1.1%
EPS of $-5.92 beat the $-6.16 estimate on $0.00 revenue.
+7.2% · S&P 500 +0.3%
Where it ended: a close of $4.36 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-5.34).
Nothing in the past 12 months.
All REVB analyst actionsNothing in the past 12 months.
All REVB dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for REVB and SPY from Benzinga historical bars. Not investment advice.
